Research programme: obesity therapeutic - MannKind CorporationAlternative Names: MKC 180
Latest Information Update: 21 Apr 2011
At a glance
- Originator MannKind Corporation
- Class Hormones; Small molecules
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Obesity
Most Recent Events
- 28 Feb 2011 Discontinued - Preclinical for Obesity in USA (Inhalation)